Edwards Lifesciences Co. (NYSE:EW) VP Sells $27,792.00 in Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now owns 22,588 shares of the company's stock, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Edwards Lifesciences Stock Up 0.6 %

EW stock traded up $0.40 during trading on Wednesday, hitting $68.79. 2,838,041 shares of the stock traded hands, compared to its average volume of 4,463,692. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $40.44 billion, a price-to-earnings ratio of 9.89, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm's 50 day moving average is $72.03 and its two-hundred day moving average is $70.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EW. Probity Advisors Inc. purchased a new position in Edwards Lifesciences in the 4th quarter worth about $295,000. Cim LLC boosted its holdings in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Cim LLC now owns 189,399 shares of the medical research company's stock valued at $14,021,000 after acquiring an additional 2,337 shares during the last quarter. Park Square Financial Group LLC bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $44,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $92,631,000. Finally, Heck Capital Advisors LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $309,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Evercore ISI reduced their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Piper Sandler raised their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.